SI1272177T1 - Postopek in farmacevtska sestava za zdravljenje rezistence proti antihipertenzivnim zdravilom in z njo povezanih stanj - Google Patents

Postopek in farmacevtska sestava za zdravljenje rezistence proti antihipertenzivnim zdravilom in z njo povezanih stanj

Info

Publication number
SI1272177T1
SI1272177T1 SI200030958T SI200030958T SI1272177T1 SI 1272177 T1 SI1272177 T1 SI 1272177T1 SI 200030958 T SI200030958 T SI 200030958T SI 200030958 T SI200030958 T SI 200030958T SI 1272177 T1 SI1272177 T1 SI 1272177T1
Authority
SI
Slovenia
Prior art keywords
melatonin
antihypertensives
formulation
related conditions
treating resistance
Prior art date
Application number
SI200030958T
Other languages
English (en)
Slovenian (sl)
Inventor
Nava Zisapel
Moshe Laudon
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Publication of SI1272177T1 publication Critical patent/SI1272177T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Indole Compounds (AREA)
SI200030958T 2000-01-05 2000-01-05 Postopek in farmacevtska sestava za zdravljenje rezistence proti antihipertenzivnim zdravilom in z njo povezanih stanj SI1272177T1 (sl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IL2000/000009 WO2001049286A1 (en) 2000-01-05 2000-01-05 Method and formulation for treating resistance to antihypertensives and related conditions

Publications (1)

Publication Number Publication Date
SI1272177T1 true SI1272177T1 (sl) 2007-10-31

Family

ID=11042938

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030958T SI1272177T1 (sl) 2000-01-05 2000-01-05 Postopek in farmacevtska sestava za zdravljenje rezistence proti antihipertenzivnim zdravilom in z njo povezanih stanj

Country Status (31)

Country Link
US (3) US7332177B1 (enExample)
EP (1) EP1272177B1 (enExample)
JP (1) JP4996803B2 (enExample)
CN (1) CN1414851A (enExample)
AT (1) ATE359072T1 (enExample)
AU (1) AU782266B2 (enExample)
BG (1) BG65637B1 (enExample)
BR (1) BR0016918A (enExample)
CA (1) CA2396129C (enExample)
CY (2) CY1108018T1 (enExample)
CZ (1) CZ299931B6 (enExample)
DE (1) DE60034373T2 (enExample)
DK (1) DK1272177T3 (enExample)
EA (1) EA004679B1 (enExample)
EE (1) EE200200379A (enExample)
ES (1) ES2284471T3 (enExample)
HK (1) HK1052655A1 (enExample)
HU (1) HU227002B1 (enExample)
IL (1) IL150190A0 (enExample)
IS (1) IS6439A (enExample)
MX (1) MXPA02005783A (enExample)
NO (1) NO322567B1 (enExample)
NZ (1) NZ520078A (enExample)
PL (1) PL201219B1 (enExample)
PT (1) PT1272177E (enExample)
SI (1) SI1272177T1 (enExample)
SK (1) SK287508B6 (enExample)
TR (1) TR200201724T2 (enExample)
TW (1) TWI260983B (enExample)
UA (1) UA77394C2 (enExample)
WO (1) WO2001049286A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US20050020666A1 (en) * 2003-07-25 2005-01-27 Dabur Research Foundation Cardioprotective agents
US20050137247A1 (en) * 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
JP3964417B2 (ja) 2004-09-27 2007-08-22 国立大学法人金沢大学 インドール誘導体を有効成分とするα２受容体遮断剤及び血管拡張剤
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
EP2633376A4 (en) * 2010-10-25 2015-02-18 Uico Inc CONTROL SYSTEM WITH A SOLID-RESISTANT TOUCH SENSOR FOR COMPLEX SURFACE GEOMETRY
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
EP3500163B1 (en) * 2016-08-18 2025-02-19 Koninklijke Philips N.V. Blood-pressure management
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
HUE070190T2 (hu) 2016-10-31 2025-05-28 Neurim Pharma 1991 Melatonin minitabletták és eljárás azok elõállítására
WO2019038586A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited PHARMACEUTICAL COMPOSITION OF MELATONIN
ES2724933A1 (es) * 2018-03-13 2019-09-17 Ocupharm Diagnostics Sl Terapia combinada con melatonina para la reducción de la presión intraocular
GB2617102A (en) * 2022-03-29 2023-10-04 John Hemming Trading Ltd Sleep therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0518468T3 (da) * 1991-05-09 2000-01-31 Neurim Pharma 1991 Melatoninholdige sammensætninger
WO1993007870A1 (en) * 1991-10-18 1993-04-29 Alza Corporation Device for the transdermal administration of melatonin
US5646049A (en) 1992-03-27 1997-07-08 Abbott Laboratories Scheduling operation of an automated analytical system
SG41955A1 (en) * 1992-04-07 1997-08-15 Neurim Pharma 1991 Use of melatonin for the manufacture of a medicament for the treatment of benign prostatic hyperplasia
EP0664339A4 (en) 1993-07-09 1999-04-28 Wakunaga Seiyaku Kk METHOD FOR DISCRIMINATION OF NUCLEIC ACIDS AND TEST KIT FOR THIS PURPOSE.
NZ298878A (en) 1995-02-01 1999-05-28 Neurim Pharma 1991 Use of melatonin to treat addiction to benzodiazepines
US5648727A (en) 1995-10-24 1997-07-15 Dpc Cirrus Inc. Capacitive level sensing pipette probe
US5700828A (en) 1995-12-07 1997-12-23 Life Resuscitation Technologies, Inc. Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions
AU2583397A (en) * 1996-04-10 1997-10-29 Chronorx, Llc Unit dosage forms, containing magnesium, vitamin c, vitamin e, folate and selenium, for treatment of vasoconstriction and related conditions
RU2134108C1 (ru) 1998-10-06 1999-08-10 Заславская Рина Михайловна Средство для лечения артериальной гипертонии, способ лечения артериальной гипертонии

Also Published As

Publication number Publication date
HU227002B1 (en) 2010-04-28
TWI260983B (en) 2006-09-01
CZ299931B6 (cs) 2008-12-29
US8075914B2 (en) 2011-12-13
DK1272177T3 (da) 2007-08-06
NO20023102L (no) 2002-08-30
ATE359072T1 (de) 2007-05-15
CY2007033I2 (el) 2009-11-04
IL150190A0 (en) 2002-12-01
HK1052655A1 (zh) 2003-09-26
AU782266B2 (en) 2005-07-14
CA2396129A1 (en) 2001-07-12
WO2001049286A1 (en) 2001-07-12
BR0016918A (pt) 2004-03-23
AU1888200A (en) 2001-07-16
EP1272177B1 (en) 2007-04-11
NO322567B1 (no) 2006-10-30
JP4996803B2 (ja) 2012-08-08
MXPA02005783A (es) 2003-10-14
BG65637B1 (bg) 2009-04-30
NO20023102D0 (no) 2002-06-27
ES2284471T3 (es) 2007-11-16
US7332177B1 (en) 2008-02-19
IS6439A (is) 2002-06-24
PT1272177E (pt) 2007-07-11
PL201219B1 (pl) 2009-03-31
CY1108018T1 (el) 2011-04-06
DE60034373T2 (de) 2007-12-20
CZ20022346A3 (cs) 2002-11-13
CY2007033I1 (el) 2009-11-04
CN1414851A (zh) 2003-04-30
US20120070501A1 (en) 2012-03-22
TR200201724T2 (tr) 2003-03-21
CA2396129C (en) 2010-11-30
UA77394C2 (uk) 2006-12-15
BG106978A (en) 2003-03-31
EE200200379A (et) 2003-10-15
PL356325A1 (en) 2004-06-28
DE60034373D1 (de) 2007-05-24
NZ520078A (en) 2004-02-27
SK9732002A3 (en) 2002-11-06
JP2003519181A (ja) 2003-06-17
US8728511B2 (en) 2014-05-20
SK287508B6 (sk) 2010-12-07
EP1272177A1 (en) 2003-01-08
HUP0204089A2 (hu) 2003-04-28
EA200200738A1 (ru) 2002-12-26
US20080085317A1 (en) 2008-04-10
EA004679B1 (ru) 2004-06-24
HUP0204089A3 (en) 2005-12-28
EP1272177A4 (en) 2004-04-28

Similar Documents

Publication Publication Date Title
IL150190A0 (en) Method and formulation for treating resistance to antihypertensives and related conditions
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
BR0109150A (pt) Método para administração de um anestésico local a um indivìduo em necessidade de um efeito anestésico local, emplastro, composição, e, recipiente
EP1423107A4 (en) FATTY ALCOHOL DRUG CONJUGATES
PL334348A1 (en) Method of treating prostate diseases using vitamin d formulations of retarded and/or prolonged release
WO2001087306A8 (en) Compositions and methods for the treatment of colorectal cancer
MXPA01006926A (es) Formulaciones para tratar enfermedades y metodos para usar las mismas.
ATE311201T1 (de) Testosteron-ester formulierung zur anwendung am menschen
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
EE200200471A (et) Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks
AU5673399A (en) Compositions and methods for treating intracellular infections
WO2001085188A3 (en) Use of echinacea as a hematinic agent
TW200637604A (en) Cosmetic compositions containing sophora alopecuroides L. extracts
AU2003219664A1 (en) Methods and therapeutic compositions in the treatment of advanced cancer
EP1490689A4 (en) NEW COMPOSITIONS AND METHODS FOR CANCER RELATED TO A CHANGED PRLR EXPRESSION
WO2002053102A3 (en) Use of iv emulsions with different triglyceride composition, particle size and apolipoprotein e for targeted tissue delivery of hydrophobic compounds
WO2001074341A3 (en) Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant
AU3924500A (en) Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
UA36261A (uk) Спосіб лікування простої шизофренії з суїцидальною поведінкою
ATE247961T1 (de) Sufentanilhaltige arzneimittel mit verzögerter wirkstoffabgabe
AU2003226859A1 (en) Use of thiophenes or bisthiophenes in compositions for the treatment of human keratin fibres compositions and methods comprising the same
AU2291102A (en) Compositions and methods for the treatment of skin damage